logo
  

Questar Q4 Results Miss Estimates; FY Outlook Weak

Natural gas company Questar Corp (STR) on Wednesday reported fourth-quarter net earnings of $62.5 million or $0.35 per share compared with $68 million or $0.39 per share last year.

The company's revenues for the quarter were lower at $373.2 million compared with $397.9 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.38 per share on revenues of $410.2 million for the quarter. Analysts' estimates typically exclude special items.

For the full year 2015, the company expects earnings of $1.20 to $1.30 per share and capital expenditures of $370 million.

Analysts expect earnings of $1.33 per share for 2015.

The company warned of challenges in 2015. The plunge in commodity prices in recent months could affect its Wexpro subsidiary's near-term ability to invest development capital in new wells that, under the terms of the Wexpro II Agreement, must be able to produce cost-of-service gas that is price-competitive with the natural gas forward price curve.

Also the company said lower gas prices would continue to make it difficult for Questar Pipeline to grow earnings in the short run due to the lack of meaningful opportunities to build new pipelines, gas storage, gathering systems and processing facilities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT